Aquinnah Pharmaceuticals
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
750 Main St, Cambridge, Massachusetts, 0...Phone Number
(617) 863-3678Website
www.aquinnahpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Aquinnah Pharmaceuticals
Aquinnah Pharmaceuticals is focused on developing innovative small molecule therapeutics for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease. The company leverages its expertise in RNA-binding proteins and biomolecular condensates to create novel drug approaches that aim to halt disease progression. With support from major pharmaceutical companies and numerous grants, Aquinnah is committed to addressing the urgent medical needs of patients facing these debilitating conditions. Their pioneering research and drug development strategies position them as a leader in the fight against neurodegenerative diseases.Explore more
Aquinnah Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aquinnah Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Aquinnah Pharmaceuticals is spiking on competitors!
Click to see if Aquinnah Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Aquinnah Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Aquinnah Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Aquinnah Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Aquinnah Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Aquinnah Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Aquinnah Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Aquinnah Pharmaceuticals
Compare insights from companies similar to Aquinnah Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aquinnah Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Aquinnah Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Aquinnah Pharmaceuticals.
Aquinnah Pharmaceuticals financials insights
Gather financial insights about Aquinnah Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$5M
2017
Private Equity
$10M
2020
Debt
$150K
2021
Debt
$138K
Aquinnah Pharmaceuticals Tech Stack
A closer look at the technologies used by Aquinnah Pharmaceuticals
Most Recent Scoops
Funding
Project
Spending/Investment, Funding
Funding
Aquinnah Pharmaceuticals has received an SBA PPP loan in the amount of $138,395 from Silicon Valley Bank resulting in the retention of 5 jobs.
Funding
Aquinnah Pharmaceuticals has received an SBA PPP loan for $150,000-350,000 from Silicon Valley Bank, supporting the retention of 6 jobs.
Funding
Aquinnah Pharmaceuticals News & Media
Aquinnah Pharmaceuticals Advances Oral Small Molecule Program Targeting Alzheimer's and Other Tauopathy Diseases
New preclinical data presented at CTAD demonstrates exciting potential for a new drug approach for Alzheimer's disease, reducing brain tau pathology by ~70% CAMBRIDGE, Mass., Oct. 30, 2023 /PRNewswire/ -- Aquinnah Pharmaceuticals announced preclinical research findings for a novel therapeutic designed to slow or stop the progression of Alzheimer's disease and related disorders. Aquinnah is a leader in pharmaceutical approaches targeting stress granule biology, which underlies the pathology of aDr. Benjamin Wolozin to Present "Development of Orally Available, Brain Penetrant Compound Reducing Tau Pathology" at CTAD 2023
Aquinnah Pharmaceutical's Co-Founder and Chief Scientific Officer to detail new preclinical research at leading Alzheimer's disease conference CAMBRIDGE, Mass., Oct. 24, 2023 /PRNewswire/ -- Aquinnah Pharmaceuticals, leaders in stress granule biology that afflict a wide range of...Aquinnah Pharmaceuticals Receives $750,000 Grant from the Alzheimer's Association and Tau Consortium to Advance New Therapies for Tauopathy Diseases
CAMBRIDGE, Mass., Jan. 17, 2019 /PRNewswire/ -- Aquinnah Pharmaceuticals, leaders in stress granule biology that afflict a wide range of neurodegenerative disorders, announced today that it has been awarded $750,000 from the Tau Pipeline Enabling Program (T-PEP) to advance its drug...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Aquinnah Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Aquinnah Pharmaceuticals is focused on developing innovative small molecule therapeutics for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease. The company leverages its expertise in RNA-binding proteins and biomolecular condensates to create novel drug approaches that aim to halt disease progressi... Read More
